This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


GlaxoSmithKline plc

Drug Names(s): talarozole, R115866

Description: Rambazole is a novel retinoic acid metabolism-blocking agent (RAMBA).

Deal Structure: In June 2008, Barrier Therapeutics announced that it has signed a definitive merger agreement with Stiefel Laboratories.

In April 2009, GlaxoSmithKline and Stiefel Laboratories announced that they have signed an agreement under which GSK will acquire Stiefel in a deal valued at up to $3.6 billion. GSK's existing prescription dermatological products will be combined with Stiefel's and the new specialist global business will operate under the Stiefel identity within the GSK Group. The acquisition was completed in July 2009.

Rambazole News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug